Literature DB >> 27867987

Modifying therapy in patients with advanced Hodgkin's lymphoma by integrating early metabolic response by interim PET-CT.

Ulrike Bacher1, Mascha Binder2.   

Abstract

Entities:  

Year:  2016        PMID： 27867987      PMCID： PMC5104656          DOI： 10.21037/atm.2016.10.20

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  16 in total

1.  Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma.

Authors:  William G Martin; Kay M Ristow; Thomas M Habermann; Joseph P Colgan; Thomas E Witzig; Stephen M Ansell
Journal:  J Clin Oncol       Date:  2005-09-26       Impact factor: 44.544

2.  Late mortality, secondary malignancy and hospitalisation in teenage and young adult survivors of Hodgkin lymphoma: report of the Childhood/Adolescent/Young Adult Cancer Survivors Research Program and the BC Cancer Agency Centre for Lymphoid Cancer.

Authors:  Kaljit S Bhuller; Yang Zhang; Dongdong Li; Laurie H Sehn; Karen Goddard; Mary L McBride; Paul C Rogers
Journal:  Br J Haematol       Date:  2016-01-05       Impact factor: 6.998

3.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors:  Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

4.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors:  Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

5.  US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.

Authors:  Oliver W Press; Hongli Li; Heiko Schöder; David J Straus; Craig H Moskowitz; Michael LeBlanc; Lisa M Rimsza; Nancy L Bartlett; Andrew M Evens; Erik S Mittra; Ann S LaCasce; John W Sweetenham; Paul M Barr; Michelle A Fanale; Michael V Knopp; Ariela Noy; Eric D Hsi; James R Cook; Mary Jo Lechowicz; Randy D Gascoyne; John P Leonard; Brad S Kahl; Bruce D Cheson; Richard I Fisher; Jonathan W Friedberg
Journal:  J Clin Oncol       Date:  2016-04-11       Impact factor: 44.544

6.  Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group.

Authors:  Dennis A Eichenauer; Indra Thielen; Heinz Haverkamp; Jeremy Franklin; Karolin Behringer; Teresa Halbsguth; Beate Klimm; Volker Diehl; Stephanie Sasse; Achim Rothe; Michael Fuchs; Boris Böll; Bastian von Tresckow; Peter Borchmann; Andreas Engert
Journal:  Blood       Date:  2014-01-29       Impact factor: 22.113

7.  Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.

Authors:  Andrea Gallamini; Martin Hutchings; Luigi Rigacci; Lena Specht; Francesco Merli; Mads Hansen; Caterina Patti; Annika Loft; Francesco Di Raimondo; Francesco D'Amore; Alberto Biggi; Umberto Vitolo; Caterina Stelitano; Rosario Sancetta; Livio Trentin; Stefano Luminari; Emilio Iannitto; Simonetta Viviani; Ivana Pierri; Alessandro Levis
Journal:  J Clin Oncol       Date:  2007-07-23       Impact factor: 44.544

8.  In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.

Authors:  Martin Hutchings; Lale Kostakoglu; Jan Maciej Zaucha; Bogdan Malkowski; Alberto Biggi; Iwona Danielewicz; Annika Loft; Lena Specht; Dominick Lamonica; Myron S Czuczman; Christina Nanni; Pier Luigi Zinzani; Louis Diehl; Richard Stern; Morton Coleman
Journal:  J Clin Oncol       Date:  2014-07-28       Impact factor: 44.544

9.  Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.

Authors:  Peter Johnson; Massimo Federico; Amy Kirkwood; Alexander Fosså; Leanne Berkahn; Angelo Carella; Francesco d'Amore; Gunilla Enblad; Antonella Franceschetto; Michael Fulham; Stefano Luminari; Michael O'Doherty; Pip Patrick; Thomas Roberts; Gamal Sidra; Lindsey Stevens; Paul Smith; Judith Trotman; Zaid Viney; John Radford; Sally Barrington
Journal:  N Engl J Med       Date:  2016-06-23       Impact factor: 91.245

Review 10.  PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas.

Authors:  Sally F Barrington; N George Mikhaeel
Journal:  Curr Hematol Malig Rep       Date:  2016-06       Impact factor: 3.952
View more
  1 in total

1.  Is interim 18F-fluoride PET/CT a predictor of outcomes after radium-223 therapy?

Authors:  Elba Etchebehere; Ana Emília Brito; Kalevi Kairemo; Eric Rohren; John Araujo; Homer Macapinlac
Journal:  Radiol Bras       Date:  2019 Jan-Feb
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.